What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone, rather than the complete hormone. FDA's December 2024 briefing identifies human growth hormone residues 177-191: a 15-amino-acid fragment with one additional N-terminal tyrosine, making 16 amino acids in the complete AOD-9604 molecule. FDA AOD-9604 assessment.
The three counts describe different things: 177-191 identifies the positions in the parent hormone, 15 counts the residues in that fragment, and 16 counts the modified peptide after the added tyrosine. FDA AOD-9604 assessment.
Results of the oral obesity study
The same December 2024 review reports that a large oral AOD-9604 obesity study did not find a significant difference in weight loss from placebo at its 12-week primary endpoint. It also records that oral development for obesity was terminated after that unsuccessful study. FDA AOD-9604 assessment.
The oral study measured weight loss after 12 weeks. The negative result does not establish successful weight loss with another presentation. It was not a direct trial of this catalogue vial. FDA AOD-9604 assessment.
AOD-9604 safety reports
FDA identifies potential immune-response and peptide-characterization risks for compounded AOD-9604. Its communication also reports serious adverse events that may be associated with AOD-9604, while stating that causality is unclear. Both parts matter: the reports are relevant safety information, but they do not prove that AOD-9604 caused every reported event. FDA compounding safety communication.
These US compounding concerns do not authenticate the supplier vial or establish its contents. The catalogue's 5MG expression is a listed amount, not a concentration or a clinical instruction. For the broader hormone context, the growth hormone overview is a separate comparison; AOD-9604 should retain its own fragment identity. FDA compounding safety communication, FDA AOD-9604 assessment.
AOD-9604 questions
Is AOD-9604 the same as full growth hormone?
No. The evaluated AOD-9604 molecule contains the 15-residue growth-hormone fragment plus an added tyrosine. The fragment definition does not justify assigning the full hormone's effects to it. FDA AOD-9604 assessment.
Does the human obesity study support a weight-loss promise?
The reviewed oral study did not show a significant weight-loss difference from placebo at its 12-week primary endpoint. It therefore cannot support a weight-loss promise for this vial. FDA AOD-9604 assessment.
